Page 33 - TD-4-1

Tumor Discovery Immunohistochemistry profiling of ovarian cysts

doi: 10.1016/j.jogoh.2018.02.002 in epithelial ovarian cancer diagnosis: From present to
future perspective. Ann Transl Med. 2017;5(13):276.
65. Rastogi M, Gupta S, Sachan, M. Biomarkers towards ovarian
cancer diagnostics: Present and future prospects. Braz Arch doi: 10.21037/atm.2017.05.13
Biol Technol. 2016;59:e16160070.
77. Iorio MV, Visone R, Di LG, et al. MicroRNA signatures in
doi: 10.1590/1678-4324-2016160070 human ovarian cancer. Cancer Res. 2007;67(18):8699-8707.
66. Macuks R, Baidekalna I, Gritcina J, Avdejeva A, Donina S. doi: 10.1158/0008-5472.CAN-07-1581
Apolipoprotein A1 and transferrin as biomarkers in ovarian
cancer diagnostics. Acta Chir Latv. 2010;10:16. 78. Steffensen KD, Alvero AB, Yang Y, et al. Prevalence of
epithelial ovarian cancer stem cells correlates with recurrence
doi: 10.2478/v10163-011-0003-3 in early-stage ovarian cancer. J Oncol. 2011;2011:620523.
67. Ahmed N, Oliva KT, Barker G, et al. Proteomic tracking of doi: 10.1155/2011/620523
serum protein isoforms as screening biomarkers of ovarian
cancer. Proteomics. 2005;5(17):4625-4636. 79. Sarojini S, Tamir A, Lim H, et al. Early detection biomarkers
for ovarian cancer. J Oncol. 2012;2012:709049.
doi: 10.1002/pmic.200401268
doi: 10.1155/2012/709049
68. Su F, Lang J, Kumar A, et al. Validation of candidate serum
ovarian cancer biomarkers for early detection. Biomark 80. Chen YL, Chang MC, Huang CY, et al. Serous ovarian
Insights. 2007;2:369-375. carcinoma patients with high alpha-folate receptor had
reducing survival and cytotoxic chemo-response. Mol
doi: 10.4137/bmi.s288 Oncol. 2012;6(3):360-369.
69. Gadomska H, Grzecocińska B, Janecki J, Nowicka G, doi: 10.1016/j.molonc.2012.04.004
Powolny M, Marianowski L. Serum lipids concentration in
women with benign and malignant ovarian tumours. Eur J 81. Yuan Y, Nymoen DA, Dong HP, et al. Expression of the
Obstet Gynecol Reprod Biol. 2005;120(1):87-90. folate receptor genes FOLR1 and FOLR3 differentiates
ovarian carcinoma from breast carcinoma and malignant
doi: 10.1016/j.ejogrb.2004.10.011 mesothelioma in serous effusions. Hum Pathol.
70. Davis M. A comprehensive review of the diagnostic and 2009;40(10):1453-1460.
treatment methods for ovarian cancer. Eur J Eng Res Sci. doi: 10.1016/j.humpath.2009.04.003
2018;3(2):13-19.
82. Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a
doi: 10.24018/ejers.2018.3.2.89 promising anti-cancer approach: Functions, molecular
71. Katchman BA, Chowell D, Wallstrom G, et al. Autoantibody mechanisms and clinical applications. Mol Cancer.
biomarkers for the detection of serous ovarian cancer. 2019;18(1):153.
Gynecol Oncol. 2017;146(1):129-136. doi: 10.1186/s12943-019-1078-2
doi: 10.1016/j.ygyno.2017.04.005 83. Hernandez L, Friedman ER, Moore RG. Emerging
72. Devarajappa GB, Kopparapu VN, Kasireddy LR, Mekala SC, biomarkers for the diagnosis of ovarian cancer. Clin Chem.
Yaraganti G. Biomarkers for early detection of ovarian 2021;67(4):679-689.
cancer: A review. Asian Pac J Cancer Biol. 2023;9(1):81-85. doi: 10.1093/clinchem/hvaa275
doi: 10.31557/APJCB.2023.9.1.81-85 84. Sundfeldt K, Piontkewitz Y, Ivarsson K. The role of Ki-67 in
73. Simon I, Zhuo S, Corral L, et al. B7-H4 is a novel membrane the diagnostic pathway of ovarian tumors. Gynecol Oncol.
bound protein and a candidate serum and tissue biomarker 2019;154(1):31-36.
for ovarian cancer. Cancer Res. 2006;66(3):1570-1575. doi: 10.1016/j.ygyno.2019.04.017
doi: 10.1158/0008-5472.CAN-05-2959 85. Zhao D, Wu Y, Song Y. The role of p53 in ovarian cancer
74. Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A. diagnosis and prognosis. J Ovarian Res. 2021;14(1):1.
Altered expression and loss of heterozygosity of the LOT1 doi: 10.1186/s13048-020-00757-8
gene in ovarian cancer. Gynecol Oncol. 2004;95(3):449-455.
86. Bast RC, Hennessy B, Mills GB. The biology of ovarian
doi: 10.1016/j.ygyno.2004.07.027 cancer: New opportunities for translation. Nat Rev Cancer.
75. Zhao X, Zhou Y, Chen YU, Yu F. miR-494 inhibits ovarian 2009;9(6):415-428.
cancer cell proliferation and promotes apoptosis by targeting doi: 10.1038/nrc2644
FGFR2. Oncol Lett. 2016;11(6):4245-4251.
87. Kaijser J, Sayasneh A, Van Holsbeke, C. Presurgical diagnosis
doi: 10.3892/ol.2016.4616
of adnexal tumors using combined biomarkers. Br J Cancer.
76. Montagnana M, Benati M, Danese E. Circulating biomarkers 2019;120(6):706-712.

Volume 4 Issue 1 (2025) 25 doi: 10.36922/td.5369